Application

Glipizide has been used in:chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assayMCF-7 breast cancer assay on chorioallantoic membrane (CAM)metastasis assaysrat aortic ring assay in vivomatrigel plug assay3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assayflow cytometrywestern blotting

Biochem/physiol Actions

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance. It is an ATP-dependent K⁺channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC). Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes. Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis.

Features and Benefits

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1). Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5)

Packaging

1 g in poly bottle

500 mg in poly bottle